Evidence map›Paper›PMID 30835784›Full record

ArticleInvestigative ophthalmology & visual science2019

Early Optic Nerve Head Glial Proliferation and Jak-Stat Pathway Activation in Chronic Experimental Glaucoma.

Diana C Lozano, Tiffany E Choe, William O Cepurna, John C Morrison, Elaine C Johnson

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. DAMPs Drive Fibroinflammatory Changes in the Glaucomatous ONH.Investigative ophthalmology & visual science · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Diana C LozanoCasey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States.
Tiffany E ChoeCasey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States.
William O CepurnaCasey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States.
John C MorrisonCasey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States.
Elaine C JohnsonCasey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States.
Oregon Health & Science University · US

Funding

Proteomics CoreP30EY010572 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Kate E Keller · 1995 to 2026
$19.4M
STUDIES IN GLAUCOMATOUS OPTIC NERVE DAMAGER01EY010145 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI MORRISON, JOHN C · 1993 to 2023
$8.9M
Translational Vision Science Research at Oregon Health & Science UniversityT32EY023211 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Yali Jia, Kate E Keller · 2013 to 2026
$2.4M
The Optic Nerve Head in GlaucomaR01EY016866 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI JOHNSON, ELAINE C · 2005 to 2008
$1.4M
NEI NIH HHS P30 EY010572NEI NIH HHS R01 EY010145NEI NIH HHS R01 EY016866NEI NIH HHS T32 EY023211
6 · The paper itself

Abstract

Purpose: We previously reported increased expression of cell proliferation and Jak-Stat pathway-related genes in chronic experimental glaucoma model optic nerve heads (ONH) with early, mild injury. Here, we confirm these observations by localizing, identifying, and quantifying ONH cellular proliferation and Jak-Stat pathway activation in this model. Methods: Chronic intraocular pressure (IOP) elevation was achieved via outflow pathway sclerosis. After 5 weeks, ONH longitudinal sections were immunolabeled with proliferation and cell-type markers to determine nuclear densities in the anterior (unmyelinated) and transition (partially myelinated) ONH. Nuclear pStat3 labeling was used to detect Jak-Stat pathway activation. Nuclear density differences between control ONH (uninjected) and ONH with either early or advanced injury (determined by optic nerve injury grading) were identified by ANOVA. Results: Advanced injury ONH had twice the nuclear density (P < 0.0001) of controls and significantly greater astrocyte density in anterior (P = 0.0001) and transition (P = 0.006) ONH regions. An increased optic nerve injury grade positively correlated with increased microglia/macrophage density in anterior and transition ONH (P < 0.0001, both). Oligodendroglial density was unaffected. In glaucoma model ONH, 80% of anterior and 66% of transition region proliferating cells were astrocytes. Nuclear pStat3 labeling significantly increased in early injury anterior ONH, and 95% colocalized with astrocytes. Conclusions: Astrocytes account for the majority of proliferating cells, contributing to a doubled nuclear density in advanced injury ONH. Jak-Stat pathway activation is apparent in the early injury glaucoma model ONH. These data confirm dramatic astrocyte cell proliferation and early Jak-Stat pathway activation in ONH injured by elevated IOP.

Indexed as

AnimalsAstrocytesBiomarkersCell ProliferationChronic DiseaseGlaucomaGlial Fibrillary Acidic ProteinImmunohistochemistryIntraocular PressureJanus KinasesMaleModels, AnimalNeurogliaOptic DiskOptic Nerve InjuriesPAX2 Transcription FactorBiomarkersGfap protein, ratGlial Fibrillary Acidic ProteinJanus KinasesPAX2 protein, ratPAX2 Transcription FactorSox2 protein, ratSOXB1 Transcription FactorsStat3 protein, ratSTAT3 Transcription Factor

Identifiers

PMID30835784
PMCPMC6402265
OpenAlexW2920732079

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.